T. Rowe Price Associates
USNA icon

T. Rowe Price Associates’s Usana Health Sciences USNA Stock Holding History

T. Rowe Price Associates’s Portfolio USNA Stock Details USNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,138
Closed -$307K – 3138
2025
Q3 		$307K Buy
11,138
+678
+6% +$20.9K ﹤0.01% 2594
2025
Q2 		$320K Buy
10,460
+1,521
+17% +$43.2K ﹤0.01% 2505
2025
Q1 		$242K Buy
8,939
+1,705
+24% +$54K ﹤0.01% 2556
2024
Q4 		$260K Buy
7,234
+985
+16% +$36.8K ﹤0.01% 2573
2024
Q3 		$237K Buy
6,249
+41
+0.7% +$1.69K ﹤0.01% 2583
2024
Q2 		$281K Buy
6,208
+359
+6% +$16.5K ﹤0.01% 2449
2024
Q1 		$284K Buy
5,849
+494
+9% +$24.2K ﹤0.01% 2459
2023
Q4 		$288K Buy
5,355
+667
+14% +$33.7K ﹤0.01% 2391
2023
Q3 		$275K Buy
4,688
+332
+8% +$20.8K ﹤0.01% 2368
2023
Q2 		$275K Buy
4,356
+122
+3% +$7.77K ﹤0.01% 2405
2023
Q1 		$267K Sell
4,234
-1,073
-20% -$64K ﹤0.01% 2402
2022
Q4 		$282K Buy
5,307
+205
+4% +$11.1K ﹤0.01% 2396
2022
Q3 		$286K Buy
5,102
+674
+15% +$44.6K ﹤0.01% 2406
2022
Q2 		$320K Buy
4,428
+771
+21% +$57.4K ﹤0.01% 2415
2022
Q1 		$291K Buy
3,657
+526
+17% +$47.4K ﹤0.01% 2559
2021
Q4 		$317K Sell
3,131
-650
-17% -$64.8K ﹤0.01% 2579
2021
Q3 		$349K Buy
3,781
+20
+0.5% +$1.92K ﹤0.01% 2525
2021
Q2 		$385K Sell
3,761
-727
-16% -$73K ﹤0.01% 2497
2021
Q1 		$438K Sell
4,488
-109
-2% -$9.92K ﹤0.01% 2433
2020
Q4 		$354K Buy
+4,597
New +$356K ﹤0.01% 2371

Other funds holding USNA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Pzena Investment Management
Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's USNA Position: Q4 2025 in Review

T. Rowe Price Associates sold out of Usana Health Sciences (USNA) in Q4 2025, closing a stake of 11,138 shares — an estimated $307K sold.

T. Rowe Price Associates first reported a position in USNA in Q4 2020 and held it in 20 quarters. The position peaked at $438K in Q1 2021. 121 funds tracked by Wall St. Rank hold USNA as of Q4 2025.

  • T. Rowe Price Associates reported no remaining Usana Health Sciences position as of Q4 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 11,138 Usana Health Sciences shares in Q4 2025, an estimated $307K.
  • T. Rowe Price Associates first reported a position in Usana Health Sciences in Q4 2020 and held it in 20 quarters.
  • T. Rowe Price Associates's Usana Health Sciences position peaked at $438K in Q1 2021.
  • 121 funds tracked by Wall St. Rank held Usana Health Sciences as of Q4 2025.

Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.